Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials

被引：0

作者：

Scheilbeler, H. ^{[1
]}

Aagren, M. ^{[2
]}

Nielsen, S. ^{[2
]}

Goodall, G. ^{[3
]}

Kotchie, R. ^{[1
]}

Valentine, W. J. ^{[3
]}

机构：

[1] IMS Hlth, London, England

[2] Novo Nordisk AS, Virum, Denmark

[3] IMS Hlth, Basel, Switzerland

来源：

VALUE IN HEALTH | 2007年 / 10卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)64973-X

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A261 / A261

页数：1

共 28 条

[1] Cost-utility of insulin detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a French setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Schejbeler, H.
Aagren, M.
Nielsen, S.
Valentine, W. J.
Goodall, G.
Kotchie, R.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A268 - A268
[2] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
[J]. DIABETOLOGIA, 2007, 50 : S428 - S428
[3] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Portugal
Silva, C.
Alves, C.
Negreiro, F.
Fonseca, M. A.
Aagren, M.
[J]. VALUE IN HEALTH, 2008, 11 (03) : A227 - A227
[4] Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/-bolus therapy for Type 1 diabetes in a UK setting. An economic evaluation based on a meta-analysis of four clinical trials
Roze, S
Palmer, AJ
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
[J]. DIABETOLOGIA, 2004, 47 : A345 - A345
[5] Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysis
Kotchie, R.
Scheijbeler, H.
Aagren, M.
Nielsen, S.
Valentine, W. J.
Goodall, G.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A222 - A222
[6] Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in an Italian setting. A meta-analysis
Aristides, M.
Kotchie, R.
Nielsen, S.
Aagren, M.
Valentine, W. J.
Goodall, G.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
[7] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Australia: A modeling evaluation based on results from a 2-year clinical trial
Fulcher, Gregory R.
Aagren, Mark
[J]. DIABETES, 2008, 57 : A338 - A339
[8] Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
Palmer, AJ
Roze, S
Valentine, WJ
Smith, I
Wittrup-Jensen, KU
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (11) : 1729 - 1746
[9] Long-term clinical outcomes of insulin detemir versus NPH based basal-bolus therapy for type I diabetes patients in Germany: A modeling analysis using results from a meta-analysis of three clinical trials
Kotchie, R. W.
Aagren, M.
Valentine, W. J.
Goodall, G.
[J]. DIABETOLOGIA, 2007, 50 : S431 - S432
[10] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
[J]. DIABETOLOGIA, 2005, 48 : A334 - A334

← 1 2 3 →